BioForm Medical Inc., a San Mateo, Calif.-based developer of an injectable dermal filler for aesthetic improvement, has set its IPO terms to 10 million common shares being offered at between $9 and $11 per share. It would have an initial market cap of approximately $490 million, were it to price at the high end of its range.
BioForm plans to trade on the Nasdaq under ticker symbol BFRM, with JPMorgan and Piper Jaffray serving as co-lead underwriters. The company has raised nearly $65 million in total VC funding since 2000, from firms like Essex Woodlands Health Ventures (20.5% pre-IPO stake), PTV Sciences (18.3%), Vivo Ventures (15.4%), Veron International Ltd. (9.6%) and Teknoinvest (9.1%).
If you do not receive this within five minutes, please try and sign in again. If the problem persists, please
email: subscriptions@peimedia.com.